Literature DB >> 9163620

Collection of peripheral blood stem cells from normal donors 60 years of age or older.

P Anderlini1, D Przepiorka, J Lauppe, D Seong, S Giralt, R Champlin, M Körbling.   

Abstract

We report 14 normal peripheral blood stem cell (PBSC) donors > or = 60 years of age who had cytokine mobilization followed by PBSC apheresis for allogeneic transplantation. Mobilization was achieved with filgrastim (6 microg/kg twice daily). Their median age was 63.5 years (range 60-77), and 43% had a positive medical history, mainly hypertension and/or cardiac problems. Their median pre-apheresis leucocyte count (x 10(9)/l) was 38.6 (range 29.6-63.4). The median apheresis yield (x 10(6) CD34+ cells/litre blood processed, first apheresis) was 27.9 (range 1.6-54.8). The target cell dose (> or = 4 x 10(6) CD34+ cells/kg recipient) was reached with one procedure in eight (57%) donors. Filgrastim-related adverse events were acceptable and apheresis was well tolerated. When compared to younger donors (< 60 years of age), a trend to a lower CD34+ apheresis yield and a requirement for more than one apheresis to achieve the collection target (> or = 4 x 10(6) CD34+ cells/kg) was evident. Although older (> or = 60 years) donors seem to mobilize less effectively, these data suggest that PBSC collection from them is feasible and has an acceptable short-term safety profile.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9163620     DOI: 10.1046/j.1365-2141.1997.302677.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

1.  Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program.

Authors:  Michael A Pulsipher; Pintip Chitphakdithai; John P Miller; Brent R Logan; Roberta J King; J Douglas Rizzo; Susan F Leitman; Paolo Anderlini; Michael D Haagenson; Seira Kurian; John P Klein; Mary M Horowitz; Dennis L Confer
Journal:  Blood       Date:  2009-02-03       Impact factor: 22.113

Review 2.  Allogeneic hematopoietic transplantation for acute and chronic myeloid leukemia: non-myeloablative preparative regimens and induction of the graft-versus-leukemia effect.

Authors:  A Shimoni; S Giralt; I Khouri; R Champlin
Journal:  Curr Oncol Rep       Date:  2000-03       Impact factor: 5.945

3.  A novel approach for the enumeration of peripheral blood stem cells suitable for transplantation.

Authors:  Winston Costa Pereira; Omar Alsuhaibani; Ghaleb Elyamany; Abdulaziz Al Abdulaaly
Journal:  J Transplant       Date:  2014-08-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.